Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of AVANZ Cupressus arizonica immunotherapy up-dosing
2013-004720-11Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Dec 2013
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cupressus arizonica pollen in allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR), sponsored by ALK-Abelló. Primary endpoint: IMP-related adverse events frequency. Started Dec 2013; status: completed.
02
Drugs
cupressus arizonica pollen
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2013-004720-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004720-11.